Privo Technologies, Inc.

Privo Technologies, Inc. is a clinical-stage biopharmaceutical company that develops localized, nanoengineered drug delivery systems designed to treat solid tumors and precancerous lesions. The company’s proprietary PRV platform utilizes specialized formulations, such as topical patches, hydrogels, and intratumoral injectables, to deliver therapeutic agents directly to the site of disease. By enabling targeted, locoregional administration, these technologies aim to maximize therapeutic efficacy while minimizing the systemic toxicity often associated with conventional cancer treatments. The company’s pipeline includes assets like PRV111, PRV131, and PRV211, which are currently being evaluated in clinical trials for conditions including oral cancer, carcinoma in situ, and various head and neck malignancies.

These innovative delivery approaches are designed to provide safer, less invasive, and more accessible treatment options for patients. By addressing limitations in traditional oncology therapies—such as the need for extensive surgery or severe side effects from systemic chemotherapy—Privo’s platform strives to improve patient quality of life and preserve healthy tissue. The company collaborates with leading institutions such as the National Cancer Institute (NCI) and top-tier clinical cancer centers to advance its multi-asset clinical programs, including the ongoing CLN-004 trial, which evaluates the safety and efficacy of its localized therapeutic strategies.